Literature DB >> 8241013

Nicorandil as a nitrate, and cromakalim as a potassium channel opener, dilate isolated porcine large coronary arteries in an agonist-nonselective manner.

K Satoh1, T Mori, H Yamada, N Taira.   

Abstract

Nicorandil is an antianginal vasodilator having a hybrid property between nitrates and potassium channel openers, and cromakalim is a relatively specific potassium channel opener. We investigated whether or not the vasorelaxant actions of the two drugs would be selective for certain vasoconstrictor agonists (simply agonists hereafter), and the underlying mechanisms in isolated porcine large coronary arteries. Both nicorandil and cromakalim produced a complete relaxation in the arteries precontracted with seven agonists, i.e., Bay-K-8644, endothelin, histamine, 5-hydroxytryptamine (5-HT), phenylephrine, PGF2 alpha, and U 46619. The EC50 values (-log M) of nicorandil and cromakalim were 5.20-5.44 and 6.43-6.87, respectively, toward the seven agonists, indicating that the vasorelaxant actions of the two drugs were agonist nonselective. In the arteries precontracted with Bay-K-8644, endothelin, 5-HT, and U 46619, the vasorelaxant action of cromakalim was antagonized by glibenclamide, an antagonist of potassium channel openers, and Schild analysis of these antagonisms yielded pA2 values of 7.10-7.41 for glibenclamide. The vasorelaxant actions of nicorandil in the arteries precontracted with the four agonists each were not antagonized by glibenclamide. Instead, the vasorelaxant action of nicorandil was antagonized by methylene blue (10 microM), an inhibitor of guanylate cyclase, and slightly potentiated by M&B 22,948 (10 microM), an inhibitor of cyclic-GMP phosphodiesterase, in the arteries precontracted with U 46619. These results indicate that the vasorelaxant actions of nicorandil and cromakalim in the porcine large coronary artery are agonist nonselective and that nicorandil exerts such an action entirely as a nitrate, whereas cromakalim does so entirely as a potassium channel opener.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8241013     DOI: 10.1007/bf00877823

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  23 in total

1.  The effects of BRL 34915 and nicorandil on electrical and mechanical activity and on 86Rb efflux in rat blood vessels.

Authors:  S W Weir; A H Weston
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

2.  Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris.

Authors:  H Kishida; S Murao
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

3.  Prinzmetal's variant form of angina with arteriographic evidence of coronary arterial spasm.

Authors:  R W Dhurandhar; D L Watt; M D Silver; A S Trimble; A G Adelman
Journal:  Am J Cardiol       Date:  1972-12       Impact factor: 2.778

4.  Coronary arterial spasm in Prinzmetal angina. Documentation by coronary arteriography.

Authors:  P B Oliva; D E Potts; R G Pluss
Journal:  N Engl J Med       Date:  1973-04-12       Impact factor: 91.245

5.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists.

Authors:  R B Parker; D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries.

Authors:  K Satoh; H Yamada; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-01       Impact factor: 3.000

8.  Pathophysiology and treatment of coronary arterial spasm.

Authors:  H Yasue
Journal:  Chest       Date:  1980-07       Impact factor: 9.410

9.  The group at C2 of N-ethylnicotinamide determines the vasodilator potencies and mechanisms of action of nicorandil and its congeners in canine coronary arteries.

Authors:  K Satoh; H Yamada; F Yoneyama; N Taira
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-11       Impact factor: 3.000

10.  Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study.

Authors:  N Hayata; H Araki; M Nakamura
Journal:  Am Heart J       Date:  1986-12       Impact factor: 4.749

View more
  1 in total

Review 1.  Potassium channel openers: clinical applications in ischemic heart disease--overview of clinical efficacy of nicorandil.

Authors:  C Knight; H Purcell; K Fox
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.